NCT03170193View on ClinicalTrials.gov

AMG 529 First in Human Study

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 15, 2017

Primary Completion Date

November 17, 2017

Study Completion Date

November 17, 2017

Conditions
Cardiovascular
Interventions
DRUG

AMG 529

Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection

DRUG

Placebo

Single doses of matching placebo by SC or IV injection

Trial Locations (1)

66212

Research Site, Overland Park

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY